The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis
Open Access
- 27 June 2023
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 13 (7) , 799
Abstract
Cholesterol has many critical functions in cells. It is a key component of membranes and cell-signalling processes, and it functions as a chemical precursor in several biochemical pathways, such as Vitamin D and steroid synthesis. Cholesterol has also been implicated in the development and progression of various cancers, in which it is thought to promote cell proliferation, migration, and invasion. Chronic lymphocytic leukemia (CLL) is an example of a lipid-avid cancer that relies on lipid metabolism, rather than glycolysis, to fuel cell proliferation. However, data regarding the role of cholesterol in CLL are conflicting. Studies have shown that dyslipidaemia is more common among CLL patients than age-matched healthy controls, and that CLL patients who take cholesterol-lowering drugs, such as statins, appear to have improved survival rates. Therefore, defining the roles of cholesterol in CLL may highlight the importance of monitoring and managing hyperlipidaemia as part of the routine management of patients with CLL. In this review, we discuss the roles of cholesterol in the context of CLL by examining the literature concerning the trafficking, uptake, endogenous synthesis, and intracellular handling of this lipid. Data from clinical trials investigating various classes of cholesterol and lipid-lowering drugs in CLL are also discussed.Keywords
Funding Information
- Cancer Council of South Australia Beat Cancer Project
- South Australian Department of Health
This publication has 89 references indexed in Scilit:
- Promising anti-leukemic activity of atorvastatinOncology Reports, 2013
- Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cellsAnnals of Hematology, 2010
- Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemiaLeukemia & Lymphoma, 2010
- Chronic lymphocytic leukaemia: a disease of activated monoclonal B cellsBest Practice & Research Clinical Haematology, 2010
- Ezetimibe Is an Inhibitor of Tumor AngiogenesisThe American Journal of Pathology, 2009
- The Potential Effect of Statins on Rituximab ImmunotherapyPLOS Medicine, 2008
- Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20PLOS Medicine, 2008
- Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathwayBiochemical Pharmacology, 2008
- Compactin (ML-236B) reduces the content of filipin-cholesterol complexes in the plasma membrane of chronic lymphocytic leukemia cellsExperimental Cell Research, 1984
- Reversible phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase in morris hepatomasBiochemical and Biophysical Research Communications, 1983